These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 34301779)

  • 1. Production and Supply of α-Particle-Emitting Radionuclides for Targeted α-Therapy.
    Radchenko V; Morgenstern A; Jalilian AR; Ramogida CF; Cutler C; Duchemin C; Hoehr C; Haddad F; Bruchertseifer F; Gausemel H; Yang H; Osso JA; Washiyama K; Czerwinski K; Leufgen K; Pruszyński M; Valzdorf O; Causey P; Schaffer P; Perron R; Maxim S; Wilbur DS; Stora T; Li Y
    J Nucl Med; 2021 Nov; 62(11):1495-1503. PubMed ID: 34301779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applications of 211At and 223Ra in targeted alpha-particle radiotherapy.
    Vaidyanathan G; Zalutsky MR
    Curr Radiopharm; 2011 Oct; 4(4):283-94. PubMed ID: 22202151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted alpha therapy: part I.
    Elgqvist J
    Curr Radiopharm; 2011 Jul; 4(3):176. PubMed ID: 22201706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which radionuclide, carrier molecule and clinical indication for alpha-immunotherapy?
    Guerard F; Barbet J; Chatal JF; Kraeber-Bodere F; Cherel M; Haddad F
    Q J Nucl Med Mol Imaging; 2015 Jun; 59(2):161-7. PubMed ID: 25752501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted alpha therapy with 213Bi.
    Morgenstern A; Bruchertseifer F; Apostolidis C
    Curr Radiopharm; 2011 Oct; 4(4):295-305. PubMed ID: 22202152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of the alpha-particle emitting radionuclides 212Bi and 213Bi, and their decay chain related radionuclides, for therapeutic applications.
    Hassfjell S; Brechbiel MW
    Chem Rev; 2001 Jul; 101(7):2019-36. PubMed ID: 11710239
    [No Abstract]   [Full Text] [Related]  

  • 7. Streptavidin in antibody pretargeting. 5. chemical modification of recombinant streptavidin for labeling with the alpha-particle-emitting radionuclides 213Bi and 211At.
    Wilbur DS; Hamlin DK; Chyan MK; Brechbiel MW
    Bioconjug Chem; 2008 Jan; 19(1):158-70. PubMed ID: 18072725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Radiotherapy with Alpha-Particle Emitting Radionuclides Seminar, November 18, 2004, Cracow, Poland.
    Zalutsky MR; Petelenz B
    Nucl Med Rev Cent East Eur; 2004; 7(2):195. PubMed ID: 15968616
    [No Abstract]   [Full Text] [Related]  

  • 9. Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators.
    Kozempel J; Mokhodoeva O; Vlk M
    Molecules; 2018 Mar; 23(3):. PubMed ID: 29510568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid preparation of short-lived alpha particle emitting radioimmunopharmaceuticals.
    Ma D; McDevitt MR; Finn RD; Scheinberg DA
    Appl Radiat Isot; 2001 Oct; 55(4):463-70. PubMed ID: 11545498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Targeted Alpha Particle Therapy for Solid Tumors.
    Tafreshi NK; Doligalski ML; Tichacek CJ; Pandya DN; Budzevich MM; El-Haddad G; Khushalani NI; Moros EG; McLaughlin ML; Wadas TJ; Morse DL
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31779154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harnessing
    Yang H; Wilson JJ; Orvig C; Li Y; Wilbur DS; Ramogida CF; Radchenko V; Schaffer P
    J Nucl Med; 2022 Jan; 63(1):5-13. PubMed ID: 34503958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunotherapy with alpha-emitting nuclides.
    McDevitt MR; Sgouros G; Finn RD; Humm JL; Jurcic JG; Larson SM; Scheinberg DA
    Eur J Nucl Med; 1998 Sep; 25(9):1341-51. PubMed ID: 9724387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy.
    Lee D; Li M; Bednarz B; Schultz MK
    Radiat Res; 2018 Sep; 190(3):236-247. PubMed ID: 29944461
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Li M; Sagastume EA; Lee D; McAlister D; DeGraffenreid AJ; Olewine KR; Graves S; Copping R; Mirzadeh S; Zimmerman BE; Larsen RH; Johnson FL; Schultz MK
    Curr Med Chem; 2020; 27(41):7003-7031. PubMed ID: 32720598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-emitters for immuno-therapy: a review of recent developments from chemistry to clinics.
    Huclier-Markai S; Alliot C; Varmenot N; Cutler CS; Barbet J
    Curr Top Med Chem; 2012; 12(23):2642-54. PubMed ID: 23339760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha Particle-Emitting Radiopharmaceuticals as Cancer Therapy: Biological Basis, Current Status, and Future Outlook for Therapeutics Discovery.
    Coll RP; Bright SJ; Martinus DKJ; Georgiou DK; Sawakuchi GO; Manning HC
    Mol Imaging Biol; 2023 Dec; 25(6):991-1019. PubMed ID: 37845582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy using alpha emitters.
    Vaidyanathan G; Zalutsky MR
    Phys Med Biol; 1996 Oct; 41(10):1915-31. PubMed ID: 8912371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.
    Zalutsky MR; Bigner DD
    Acta Oncol; 1996; 35(3):373-9. PubMed ID: 8679269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innovation, Impact, and Strategic Importance of Alpha-Emitting Radionuclides.
    Mirzadeh S
    J Med Imaging Radiat Sci; 2019 Dec; 50(4 Suppl 1):S21-S25. PubMed ID: 31420270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.